News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Subscribe To Our Newsletter & Stay Updated
